NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2023 Mar 13

PMID 36907961

Authors

Herbert H Loong

Abha Gupta

Alessandro Gronchi

Affiliations

Soon will be listed here.

References

Kasper B, Raut C, Gronchi A . Desmoid tumors: To treat or not to treat, That is the question. Cancer. 2020; 126(24):5213-5221. DOI: 10.1002/cncr.33233. View

Colombo C, Fiore M, Grignani G, Tolomeo F, Merlini A, Palassini E . A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. Clin Cancer Res. 2022; 28(18):4027-4032. DOI: 10.1158/1078-0432.CCR-21-4205. View

Tsukada K, Church J, Jagelman D, Fazio V, McGannon E, George C . Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum. 1992; 35(1):29-33. DOI: 10.1007/BF02053335. View

Nishida Y, Tsukushi S, Shido Y, Urakawa H, Arai E, Ishiguro N . Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality. Cancers (Basel). 2013; 4(1):88-99. PMC: 3712685. DOI: 10.3390/cancers4010088. View

Pires de Camargo V, Keohan M, DAdamo D, Antonescu C, Brennan M, Singer S . Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010; 116(9):2258-65. PMC: 2925106. DOI: 10.1002/cncr.25089. View

Constantinidou A, Jones R, Scurr M, Al-Muderis O, Judson I . Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009; 45(17):2930-4. DOI: 10.1016/j.ejca.2009.08.016. View

Palassini E, Frezza A, Mariani L, Lalli L, Colombo C, Fiore M . Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. Cancer J. 2017; 23(2):86-91. DOI: 10.1097/PPO.0000000000000254. View

Skapek S, Ferguson W, Granowetter L, Devidas M, Perez-Atayde A, Dehner L . Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007; 25(5):501-6. DOI: 10.1200/JCO.2006.08.2966. View

Heinrich M, McArthur G, Demetri G, Joensuu H, Bono P, Herrmann R . Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006; 24(7):1195-203. DOI: 10.1200/JCO.2005.04.0717. View

10.

Penel N, Le Cesne A, Bui B, Perol D, Brain E, Ray-Coquard I . Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2010; 22(2):452-7. DOI: 10.1093/annonc/mdq341. View

11.

Chugh R, Wathen J, Patel S, Maki R, Meyers P, Schuetze S . Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010; 16(19):4884-91. DOI: 10.1158/1078-0432.CCR-10-1177. View

12.

Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R . Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017; 76:60-67. DOI: 10.1016/j.ejca.2017.02.001. View

13.

Gounder M, Mahoney M, Van Tine B, Ravi V, Attia S, Deshpande H . Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018; 379(25):2417-2428. PMC: 6447029. DOI: 10.1056/NEJMoa1805052. View

14.

Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C . Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019; 20(9):1263-1272. DOI: 10.1016/S1470-2045(19)30276-1. View

15.

Kummar S, OSullivan Coyne G, Do K, Turkbey B, Meltzer P, Polley E . Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol. 2017; 35(14):1561-1569. PMC: 5455706. DOI: 10.1200/JCO.2016.71.1994. View

16.

Cesne A, Ray-Coquard I, Bui B, Adenis A, Rios M, Bertucci F . Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010; 11(10):942-9. DOI: 10.1016/S1470-2045(10)70222-9. View